title: Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.
abstract: OBJECTIVE
  To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary clinical outcomes.
  
  
  RESULTS
  We studied 5745 ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention (PCI) in APEX-AMI. Approximately 11% had AF during hospitalization. Atrial fibrillation prevalence at baseline and at discharge was 4.8% [confidence interval (CI) 4.3-5.4%] and 2.5% (CI 2.1-2.9%), respectively. The proportion of 5466 patients without AF at baseline who developed new onset AF was 6.3% (CI 5.6-6.9%). This corresponded to 9.3 cases of new onset AF/1000 patient days at risk. New onset AF was independently associated with 90 day mortality [adjusted hazard ratio (HR) 1.81; 95% CI 1.06-3.09; P = 0.029] after accounting for baseline covariates and in-hospital procedures and complications. New onset AF was associated with shock (adjusted HR 3.81; 95% CI 1.88-7.70; P = 0.0002), congestive heart failure (adjusted HR 2.66; 95% CI 1.74-4.06; P < 0.0001), and stroke (adjusted HR 2.98; 95% CI 1.47-6.04; P = 0.0024) in models accounting for baseline covariates. Of AF patients, 55% did not receive oral anticoagulation therapy at discharge. Among patients with coronary stents, 5.1% were discharged on triple therapy. Patients at highest risk of stroke (CHADS(2) score > or =2) were least likely to receive oral anticoagulation at discharge (39%). Warfarin use in patients with AF at discharge (43.4%) was associated with lower rates of 90 day mortality and stroke.
  
  
  CONCLUSIONS
  Atrial fibrillation prevalence at baseline and at discharge was 4.8 and 2.5%, respectively. The proportion of patients who developed new onset AF was 6.3%. New onset AF was independently associated with 90 day mortality and was a marker of adverse outcomes in patients undergoing primary PCI.
authors.affiliation: Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA.
authors.forename: Renato D
authors.initials: RD
authors.lastname: Lopes
authors.forename: Laine E
authors.initials: LE
authors.lastname: Elliott
authors.forename: Harvey D
authors.initials: HD
authors.lastname: White
authors.forename: Judith S
authors.initials: JS
authors.lastname: Hochman
authors.forename: Frans
authors.initials: F
authors.lastname: Van de Werf
authors.forename: Diego
authors.initials: D
authors.lastname: Ardissino
authors.forename: Torsten T
authors.initials: TT
authors.lastname: Nielsen
authors.forename: W Douglas
authors.initials: WD
authors.lastname: Weaver
authors.forename: Petr
authors.initials: P
authors.lastname: Widimsky
authors.forename: Paul W
authors.initials: PW
authors.lastname: Armstrong
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Granger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001281:Atrial Fibrillation / Q000209:etiology* / Q000401:mortality; D003169:Complement Inactivator Proteins / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D057127:Single-Chain Antibodies / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003169:Complement Inactivator Proteins; D005343:Fibrinolytic Agents; D057127:Single-Chain Antibodies; C402724:pexelizumab